Search results
5 days ago · Today, a global team of researchers funded by a Stand Up To Cancer® (SU2C) grant announced clinical trial results that point to a new immunotherapy treatment option for two of the most common types of soft tissue sarcoma in adults, a breakthrough that reduces the risk of relapse by 43% at two years and will likely impact clinical practice for ...
4 days ago · LOS ANGELES, Calif. – For the last three decades, breakthroughs have been sparse for soft tissue sarcomas, which are rare cancers that affect muscles, fat and other connective tissues. Today, a global team of researchers funded by a Stand Up To Cancer® (SU2C) grant announced clinical trial results that point to a new immunotherapy treatment option for two of the most common types of soft ...
6 days ago · Osimertinib is a recommended treatment for advanced non–small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation and as adjuvant treatment for resected EGFR ...
5 days ago · The late Laura Ziskin and the late Noreen Fraser are also co-founders. Julian Adams , Ph.D., serves as SU2C's president and CEO. For more information, visit StandUpToCancer.org , Instagram ...
3 days ago · LBA4 Background: EGFR mutations occur in up to one-third of pts with unresectable stg III NSCLC. Consolidation durvalumab is standard of care (SoC) for pts who do not progress after concurrent CRT (cCRT), yet the benefit of consolidation immunotherapy specifically for EGFRm NSCLC remains uncertain, with limited data available. Osi, a 3rd-generation CNS-active EGFR-TKI, is recommended for EGFRm ...
6 days ago · First and only EGFR inhibitor and targeted treatment to show benefit in Stage III setting, extending progression-free survival by more than three years. Positive results from the LAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in ...
6 days ago · The LAURA trial is the first phase 3 study to assess a targeted agent in patients with unresectable stage III NSCLC. It included a total of 216 patients from 17 countries randomly assigned 2:1 to receive either osimertinib (143 patients) or placebo (73) patients. The majority of patients in the study were female (63% in the osimertinib group ...
